At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Advancements in our understanding of genetics have the potential to change the practice of medicine and enable genomics-based healthcare. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than ever before. Together, we can address healthcare in ways never before imagined. Visit the Illumina booth to find out how.
TruSight Oncology ctDNA is a pan-cancer NGS assay that enables in-house CGP from blood plasma. The panel is designed to analyze 523 cancer-relevant genes and identify key biomarkers in guidelines in clinical trials, including the immuno-oncology markers TMB and MSI. *Enable Comprehensive Genomic Profiling from Plasma Pan-cancer CGP assay aligned with key guidelines and trials Similar DNA content as TruSight Oncology 500, including full coding sequence of 523 genes Detects single nucleotide variants (SNVs), Indels, CNVs, fusions, and IO biomarkers *Implement In-house CGP with an Integrated Workflow Streamlined 5-day workflow from cfDNA results Rapid variant calling algorithm powered by DRAGEN Analysis Software and the DRAGEN Server v3 Integrated interpretation report available through Clinical Genomics Workspace from Pierian Dx *Achieve Confidence in Results More confident results with hybrid-capture chemistry, unique molecular indices (UMI) and sophisticated error correction Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection Deep sequencing provided by the NovaSeq 6000 and more affordability with the v1.5 Reagent Kits *Unlock Liquid Biopsy, Including Valuable IO Insights Obtain the sensitivity and specificity required for low-level variant detection in plasma Unlock CGP insights from liquid biopsy with or without precious tissue samples Broad 1.94 Mb panel ideal for IO biomarkers such as TMB and MSI (now with >2400 homopolymer sites)